Skip to main content

Advertisement

SpringerLink
Log in

Effect of the Anti-retroviral Drugs Efavirenz, Tenofovir and Emtricitabine on Endothelial Cell Function: Role of PARP

  • Published:
Cardiovascular Toxicology Aims and scope Submit manuscript

Abstract

Highly active anti-retroviral therapy has proved successful in reducing morbidity and mortality associated with HIV infection though it has been linked to increased risk of cardiovascular disease. To date, the direct effects of the anti-retroviral drugs Efavirenz, Tenofovir and Emtricitabine on the vasculature relaxant response have not been elucidated, which impaired may predispose individuals to cardiovascular disease. Increased cellular oxidative stress and overactivation of the DNA repair enzyme poly (ADP-ribose) polymerase (PARP) have been identified as central mediators of vascular dysfunction. The aim of this study was to investigate whether exposure to Efavirenz, Tenofovir or Emtricitabine directly causes endothelial cell dysfunction via overactivation of PARP. Exposure of ex vivo male rat aortic rings or in vitro endothelial cells to Efavirenz but not Tenofovir or Emtricitabine impaired the acetylcholine-mediated relaxant response, increased cellular oxidative stress and PARP activity, decreased cell viability and increased apoptosis and necrosis. Pharmacological inhibition of PARP protected against the Efavirenz-mediated impairment of vascular relaxation and endothelial cell dysfunction. Oestrogen exposure also protected against the Efavirenz-mediated inhibition of the vascular relaxant response, cell dysfunction and increased PARP activation. In conclusion, Efavirenz directly impairs endothelial cell function, which may account for the increased risk of developing cardiovascular complications with anti-retroviral therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Apostolova, N., Blas-Garcia, A., & Esplugues, J. V. (2011). Mitochondrial interference by anti-HIV drugs: mechanisms beyond Pol-gamma inhibition. Trends in Pharmacological Sciences, 32, 715–725.

    Article  CAS  PubMed  Google Scholar 

  2. Pacher, P., Beckman, J. S., & Liaudet, L. (2007). Nitric oxide and peroxynitrite in health and disease. Physiological Reviews, 87, 315–424.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Gao, R. Y., Mukhopadhyay, P., Mohanraj, R., Wang, H., Horvath, B., Yin, S., et al. (2011). Resveratrol attenuates azidothymidine-induced cardiotoxicity by decreasing mitochondrial reactive oxygen species generation in human cardiomyocytes. Molecular Medicine Reports, 4, 151–155.

    CAS  PubMed  Google Scholar 

  4. Jiang, B., Hebert, V. Y., Li, Y., Mathis, J. M., Alexander, J. S., & Dugas, T. R. (2007). HIV antiretroviral drug combination induces endothelial mitochondrial dysfunction and reactive oxygen species production, but not apoptosis. Toxicology and Applied Pharmacology, 224, 60–71.

    Article  CAS  PubMed  Google Scholar 

  5. Worm, S. W., Sabin, C., Weber, R., Reiss, P., El-Sadr, W., Dabis, F., et al. (2010). Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. Journal of Infectious Diseases, 201, 318–330.

    Article  CAS  PubMed  Google Scholar 

  6. Gupta, S. K., Shen, C., Moe, S. M., Kamendulis, L. M., Goldman, M., & Dube, M. P. (2012). Worsening endothelial function with efavirenz compared to protease inhibitors: a 12-month prospective study. PLoS ONE, 7, e45716.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Maggi, P., Bellacosa, C., Carito, V., Perilli, F., Lillo, A., Volpe, A., et al. (2011). Cardiovascular risk factors in patients on long-term treatment with nevirapine- or efavirenz-based regimens. Journal of Antimicrobial Chemotherapy, 66, 896–900.

    Article  CAS  PubMed  Google Scholar 

  8. Gleason, R. L., Jr., Caulk, A. W., Seifu, D., Rosebush, J. C., Shapiro, A. M., Schwartz, M. H., et al. (2016). Efavirenz and ritonavir-boosted lopinavir use exhibited elevated markers of atherosclerosis across age groups in people living with HIV in Ethiopia. Journal of Biomechanics, 49, 2584–2592.

    Article  PubMed  Google Scholar 

  9. Durand, M., Sheehy, O., Baril, J. G., Lelorier, J., & Tremblay, C. L. (2011). Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Quebec’s public health insurance database. Journal of Acquired Immune Deficiency Syndromes, 57, 245–253.

    Article  PubMed  Google Scholar 

  10. Kim, C., Gupta, S. K., Green, L., Taylor, B. M., Deuter-Reinhard, M., Desta, Z., et al. (2011). Abacavir, didanosine and tenofovir do not induce inflammatory, apoptotic or oxidative stress genes in coronary endothelial cells. Antiviral Therapy, 16, 1335–1339.

    Article  CAS  PubMed  Google Scholar 

  11. De Pablo, C., Orden, S., Calatayud, S., Marti-Cabrera, M., Esplugues, J. V., & Alvarez, A. (2012). Differential effects of tenofovir/emtricitabine and abacavir/lamivudine on human leukocyte recruitment. Antiviral Therapy, 17, 1615–1619.

    Article  PubMed  Google Scholar 

  12. Jamaluddin, M. S., Lin, P. H., Yao, Q., & Chen, C. (2010). Non-nucleoside reverse transcriptase inhibitor efavirenz increases monolayer permeability of human coronary artery endothelial cells. Atherosclerosis, 208, 104–111.

    Article  CAS  PubMed  Google Scholar 

  13. Apostolova, N., Gomez-Sucerquia, L. J., Moran, A., Alvarez, A., Blas-Garcia, A., & Esplugues, J. V. (2010). Enhanced oxidative stress and increased mitochondrial mass during Efavirenz-induced apoptosis in human hepatic cells. British Journal of Pharmacology, 160, 2069–2084.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Blas-Garcia, A., Apostolova, N., Ballesteros, D., Monleon, D., Morales, J. M., Rocha, M., et al. (2010). Inhibition of mitochondrial function by efavirenz increases lipid content in hepatic cells. Hepatology, 52, 115–125.

    Article  CAS  PubMed  Google Scholar 

  15. Hulgan, T., Morrow, J., D’Aquila, R. T., Raffanti, S., Morgan, M., Rebeiro, P., et al. (2003). Oxidant stress is increased during treatment of human immunodeficiency virus infection. Clinical Infectious Diseases, 37, 1711–1717.

    Article  CAS  PubMed  Google Scholar 

  16. Edgell, C. J., McDonald, C. C., & Graham, J. B. (1983). Permanent cell line expressing human factor VIII-related antigen established by hybridization. Proceedings of the National Academy of Sciences, 80, 3734–3737.

    Article  CAS  Google Scholar 

  17. Garcia Soriano, F., Virag, L., Jagtap, P., Szabo, E., Mabley, J. G., Liaudet, L., et al. (2001). Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nature Medicine, 7, 108–113.

    Article  CAS  PubMed  Google Scholar 

  18. Helyar, S. G., Patel, B., Headington, K., El Assal, M., Chatterjee, P. K., Pacher, P., et al. (2009). PCB-induced endothelial cell dysfunction: role of poly(ADP-ribose) polymerase. Biochemical Pharmacology, 78, 959–965.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Mabley, J. G., Suarez-Pinzon, W. L., Hasko, G., Salzman, A. L., Rabinovitch, A., Kun, E., et al. (2001). Inhibition of poly (ADP-ribose) synthetase by gene disruption or inhibition with 5-iodo-6-amino-1,2-benzopyrone protects mice from multiple-low-dose-streptozotocin-induced diabetes. British Journal of Pharmacology, 133, 909–919.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Jagtap, P., Soriano, F. G., Virag, L., Liaudet, L., Mabley, J., Szabo, E., et al. (2002). Novel phenanthridinone inhibitors of poly (adenosine 5′-diphosphate-ribose) synthetase: potent cytoprotective and antishock agents. Critical Care Medicine, 30, 1071–1082.

    Article  CAS  PubMed  Google Scholar 

  21. Virag, L., Robaszkiewicz, A., Rodriguez-Vargas, J. M., & Oliver, F. J. (2013). Poly(ADP-ribose) signaling in cell death. Molecular Aspects of Medicine, 34, 1153–1167.

    Article  CAS  PubMed  Google Scholar 

  22. Soriano, F. G., Pacher, P., Mabley, J., Liaudet, L., & Szabo, C. (2001). Rapid reversal of the diabetic endothelial dysfunction by pharmacological inhibition of poly(ADP-ribose) polymerase. Circulation Research, 89, 684–691.

    Article  CAS  PubMed  Google Scholar 

  23. Marzolini, C., Telenti, A., Decosterd, L. A., Greub, G., Biollaz, J., & Buclin, T. (2001). Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS, 15, 71–75.

    Article  CAS  PubMed  Google Scholar 

  24. Burger, D., van der Heiden, I., la Porte, C., van der Ende, M., Groeneveld, P., Richter, C., et al. (2006). Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. British Journal of Clinical Pharmacology, 61, 148–154.

    Article  CAS  PubMed  Google Scholar 

  25. la Porte, C. J., Sabo, J. P., Beique, L., & Cameron, D. W. (2009). Lack of effect of efavirenz on the pharmacokinetics of tipranavir-ritonavir in healthy volunteers. Antimicrobial Agents and Chemotherapy, 53, 4840–4844.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Andrabi, S. A., Dawson, T. M., & Dawson, V. L. (2008). Mitochondrial and nuclear cross talk in cell death: parthanatos. Annals of the New York Academy of Sciences, 1147, 233–241.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Yu, S. W., Andrabi, S. A., Wang, H., Kim, N. S., Poirier, G. G., Dawson, T. M., et al. (2006). Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death. Proceedings of the National Academy of Sciences, 103, 18314–18319.

    Article  CAS  Google Scholar 

  28. Chen, M., Zsengeller, Z., Xiao, C. Y., & Szabo, C. (2004). Mitochondrial-to-nuclear translocation of apoptosis-inducing factor in cardiac myocytes during oxidant stress: potential role of poly(ADP-ribose) polymerase-1. Cardiovascular Research, 63, 682–688.

    Article  CAS  PubMed  Google Scholar 

  29. Liu, F., Jiang, N., Xiao, Z. Y., Cheng, J. P., Mei, Y. Z., Zheng, P., et al. (2016). Effects of poly (ADP-ribose) polymerase-1 (PARP-1) inhibition on sulfur mustard-induced cutaneous injuries in vitro and in vivo. PeerJ, 4, e1890.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Weiss, M., Kost, B., Renner-Muller, I., Wolf, E., Mylonas, I., & Bruning, A. (2016). Efavirenz causes oxidative stress, endoplasmic reticulum stress, and autophagy in endothelial cells. Cardiovascular Toxicology, 16, 90–99.

    Article  CAS  PubMed  Google Scholar 

  31. Molina, J. M., Peytavin, G., Perusat, S., Lascoux-Combes, C., Sereni, D., Rozenbaum, W., et al. (2004). Pharmacokinetics of emtricitabine, didanosine and efavirenz administered once-daily for the treatment of HIV-infected adults (pharmacokinetic substudy of the ANRS 091 trial). HIV Medicine, 5, 99–104.

    Article  CAS  PubMed  Google Scholar 

  32. Markowitz, M., Zolopa, A., Squires, K., Ruane, P., Coakley, D., Kearney, B., et al. (2014). Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults. Journal of Antimicrobial Chemotherapy, 69, 1362–1369.

    Article  CAS  PubMed  Google Scholar 

  33. Neumann, T., Woiwod, T., Neumann, A., Ross, B., Von Birgelen, C., Volbracht, L., et al. (2004). Cardiovascular risk factors and probability for cardiovascular events in HIV-infected patients. Part II: gender differences. European Journal of Medical Research, 9, 55–60.

    PubMed  Google Scholar 

  34. Triant, V. A., Lee, H., Hadigan, C., & Grinspoon, S. K. (2007). Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. Journal of Clinical Endocrinology and Metabolism, 92, 2506–2512.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Mabley, J. G., Horvath, E. M., Murthy, K. G., Zsengeller, Z., Vaslin, A., Benko, R., et al. (2005). Gender differences in the endotoxin-induced inflammatory and vascular responses: potential role of poly(ADP-ribose) polymerase activation. Journal of Pharmacology and Experimental Therapeutics, 315, 812–820.

    Article  CAS  PubMed  Google Scholar 

  36. Zaremba, T., Ketzer, P., Cole, M., Coulthard, S., Plummer, E. R., & Curtin, N. J. (2009). Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines. British Journal of Cancer, 101, 256–262.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Zhang, F., Wang, Y., Wang, L., Luo, X., Huang, K., Wang, C., et al. (2013). Poly(ADP-ribose) polymerase 1 is a key regulator of estrogen receptor alpha-dependent gene transcription. Journal of Biological Chemistry, 288, 11348–11357.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Jog, N. R., & Caricchio, R. (2013). Differential regulation of cell death programs in males and females by Poly (ADP-Ribose) Polymerase-1 and 17beta estradiol. Cell Death and Disease, 4, e758.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Wing, L. Y., Chen, Y. C., Shih, Y. Y., Cheng, J. C., Lin, Y. J., & Jiang, M. J. (2009). Effects of oral estrogen on aortic ROS-generating and -scavenging enzymes and atherosclerosis in apoE-deficient mice. Experimental Biology and Medicine (Maywood), 234, 1037–1046.

    Article  CAS  Google Scholar 

  40. Wong, C. M., Yung, L. M., Leung, F. P., Tsang, S. Y., Au, C. L., Chen, Z. Y., et al. (2008). Raloxifene protects endothelial cell function against oxidative stress. British Journal of Pharmacology, 155, 326–334.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Mary Faltz was supported by the Fonds National De La Recherche in Luxembourg (Reference 1007977).

Author information

Authors and Affiliations

  1. School of Pharmacy and Biomolecular Sciences, University of Brighton, Huxley Building, Lewes Road, Brighton, BN2 4GJ, UK

    Mary Faltz, Hild Bergin, Guy Grimwade & Jon G. Mabley

  2. Brighton and Sussex Medical School, University of Sussex, Brighton, BN1 9PX, UK

    Elly Pilavachi

Authors
  1. Mary Faltz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hild Bergin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elly Pilavachi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Guy Grimwade
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jon G. Mabley
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jon G. Mabley.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Faltz, M., Bergin, H., Pilavachi, E. et al. Effect of the Anti-retroviral Drugs Efavirenz, Tenofovir and Emtricitabine on Endothelial Cell Function: Role of PARP. Cardiovasc Toxicol 17, 393–404 (2017). https://doi.org/10.1007/s12012-016-9397-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12012-016-9397-4

Keywords

Search

Navigation